Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling

Executive Summary

In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.

You may also be interested in...



Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'

Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative”. The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.

From Supply Chain To Value Chain: OPPI’s Matai On Moving ‘Up’ Amidst Winds Of Policy Change In India

Incoming director general of the Organisation of Pharmaceutical Producers of India discusses the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices could be focus in the coming year, Anil Matai adds.

OPPI’s Matai On Winds Of Policy Change In India, Quality Oversight

Incoming director general of the Organisation of Pharmaceutical Producers of India, Anil Matai, talks to Scrip about the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices and transparency in interactions between pharma and physicians could be key focus areas in the coming year, he adds.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel